Understanding Lung Cancer Part 3: Your Immune System and Today’s Treatment Options 

2026-01-05T15:55:16-06:00January 5th, 2026|Newsletter Articles, Your Community|

By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  This is the third blog post of our ongoing “Understanding Lung Cancer” series. This series aims to simplify the science behind lung cancer and help provide a deeper understanding [...]

FDA Approves New Combination Therapy for People with Advanced EGFR+ NSCLC

2024-09-20T10:29:57-05:00September 20th, 2024|Hot Topics, News, Science and Research|

On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this [...]

Go to Top